Superluminal Medicines宣布完成新一轮融资，此轮融资由Bvf Partners领投。值得注意的是，包括英伟达（NVIDIA）、礼来（Eli Lilly & Co）、Cooley以及Gaingels在内的多家现有投资方亦参与了本轮投资，阵容堪称豪华。
这笔资金将如何运用？公司方面并未披露具体细节。不过，从参与方的构成来看——既有全球顶尖的半导体巨头，又有制药领域的重量级玩家——这轮融资的产业协同意味相当浓厚。投资方跨越科技与生物医药两大领域的布局，似乎也暗示着Superluminal Medicines未来的发展方向可能涉及计算驱动的药物发现。
截至目前，Superluminal Medicines尚未透露本次融资的具体金额及公司估值。市场对此番资本运作的关注，或许更多聚焦于这组罕见投资组合背后所蕴含的战略意图。毕竟，当芯片龙头与制药巨擘同时出现在一家初创公司的股东名单上，释放出的信号远不止是"钱到位了"那么简单。
随着这笔资金的落袋，Superluminal Medicines接下来会有何动作？业界正拭目以待。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.